About UsUnderstanding AMLInterviewsGlobal NetworkGet InvolvedStoriesResources

What updates are there on the VIALE-C trial for AML patients?

Andrew Wei

July 16, 2020

During the 25th Congress of the European Hematology Association (EHA), KnowAML spoke to Andrew Wei, The Alfred, Melbourne. We asked: What updates are there on the VIALE-C trial, and what do they mean for patients with AML? Elderly patients with AML are often ineligible for intensive therapy, and are mostly treated at lower doses with a chemotherapy agent called cytarabine (Ara-C). The VIALE-C study is a phase III clinical trial designed with an aim to improve patient outcomes to therapy and expand the treatment options for elderly patients with AML. Venetoclax is a newer treatment, which causes death of leukemic cells and is more targeted than conventional chemotherapy. The VIALE-C trial is looking at whether the addition of venetoclax to low-dose Ara-C could improve elderly patients responses to therapy. Patient response rates were substantially higher when treated with venetoclax + Ara-C compared with Ara-C + a placebo tablet.